FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Sandercock Colin						2. Issuer Name and Ticker or Trading Symbol Cue Biopharma, Inc. [CUE]								tionship of Reporting Pers all applicable) Director Officer (give title			ner
(Last) 21 ERIE	(Last) (First) (Middle) 21 ERIE STREET					3. Date of Earliest Transaction (Month/Day/Year) 03/06/2019								General Coun		Other (s below) sel and Sec	·
(Street) CAMBRIDGE MA 02139 (City) (State) (Zip)					4. If Amendment, Date of Original Filed (Month/Day/Year)								dividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(3	•	.ble I - Non-	Derivat	ive S	ecuritie	s Ac	cauired. C)isn	osed o	of, or Be	neficiall	v Owned				
1. Title of Security (Instr. 3) 2. Trans Date				2. Transact	ion	2A. Deem Execution if any	A. Deemed execution Date,		3. Transaction Code (Instr.		ities Acquir		5. Amour Securities Beneficia Owned Fe	5. Amount of Securities Beneficially Dwned Following		: Direct I Indirect I str. 4)	7. Nature of Indirect Beneficial Ownership
								Code	/	Amount	nt (A) or P		Reported Transacti (Instr. 3 a	Transaction(s) (Instr. 3 and 4)		[(Instr. 4)
			Table II - D (e					uired, Dis , options	•		,	,	Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Ye	Code	saction (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisab Expiration Date (Month/Day/Year)		of Securities		ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securitie Beneficia Owned Following Reported Transacti	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable		kpiration ate	Title	Amount or Number of Shares		(Instr. 4)	ion(s)		
Stock Option (right to buy)	\$6.42	03/06/2019		A		50,000		(1)	03	3/06/2029	Common Stock	50,000	\$0.00	50,00	00	D	
Stock Option (right to buy)	\$7.5	03/06/2019		A		100,000		(2)	12	2/27/2024	Common Stock	100,000	\$0.00	100,0	00	D	

Explanation of Responses:

Remarks:

/s/ Colin Sandercock by Mark Busch, as attorney-in-fact

03/08/2019

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $^{1. \} This stock option grant becomes exercisable in eight equal semi-annual installments beginning September 6, 2019.$

^{2.} Represents a stock option award granted on December 27, 2017 that partially vested upon the achievement of certain performance based conditions as determined by the Compensation Committee of Cue Biopharma, Inc. on March 6, 2019. As of March 6, 2019, 65,000 of these options were vested and exercisable. The remaining 35,000 will become vested and exercisable only upon the achievement of certain performance based conditions.